Author/year

Country

Study design/Number of Cases

Intervention

Type

Route

Type of DM

Apply Frequency

Duration of Treatments (weeks)

Number of patients

Age/Ulcer location

Wagner grade

Complete healing/ Ulcer duration

Diabetic Duration

Fernandez-Montequin (2019)

Cuban

RCT

20

rhEGF 75 μg (n = 53)

Intralesional

Type 1

and 2

3 times per

week

8 weeks

149

65.5/ Foot

Grades 3 or

4

60%/4.3 weeks

15 years

rhEGF 25 μg (n = 48)

Injection

Sanjeev Singla (2014)

India

RCT

1

Betadine/Urogastrone (rhEGF) gel 15

Topically

Type 1 and 2

Once every two

weeks

8 weeks

50

55-58/Foot

Grade 1 or 2

22.46%/NA

NA

Kwang Hwan Park (2018)

South

Korea

RCT

6

EGF 0.005%/Normal saline

Topically

Type 1

and 2

Twice a day

12 weeks

167

56-59/Foot

Grades 1 or 2

62%/NA

NA

Thambi Durai David (2018)

India

RCT

NA

EGF Cream

150 g

Topically

NA

NA

4 weeks

50

25-75/Foot

Grade 1-2

78%

4 weeks

NA

Prabakar (2016)

India

RCT

1

rhEGF/saline

Topically

NA

NA

14 weeks

60

20-70/Foot

Grades 2

75%

NA

NA

Viswanathan (2019)

India

RCT

1

hEGH gel (Regen-D)/Placebo

Topically

Type 1

and2

NA

4 weeks

50

55-57/Foot and thigh

Grades 1,

and 2

45%

NA

NA

Ajay Kundal (2020)

Indian

RCT

1

(EGF)/Conventional Betadine dressing

Topically

NA

NA

8 weeks

60

30-71/Foot

NA

58%

8

NA

Gomez-Villa (2014)

Mexico

RCT

2

rhEGF (75 μg)/Placebo

Intralesional

Injection

Type 1

and 2

3 times per week

8 weeks

34

58.6/Foot

Grades 1, 2

and 3

12%

8

16.3

Years